Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 6 Neuroendocrine Tumors 2 Gastro-enteropancreatic neuroendocrine tumor 2 Digestive System Neoplasms 2 Urogenital Neoplasms 1 Stomach Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Prostatic Diseases 1 Prostate Cancer Metastatic 1 Pancreatic Neoplasms 1 Pancreatic Diseases 1 Oligometastatic Prostate Cancer (OMPC) 1 Neuroectodermal Tumors 1 Neoplasms, Nerve Tissue 1 Neoplasms, Germ Cell and Embryonal 1 Neoplasms by Site 1 Neoplasms by Histologic Type 1 Neoplasms 1 Metastatic Castration-Resistant Prostate Cancer 1 Lung Neoplasms 1 Intestinal Neoplasms 1 Intestinal Diseases 1 Gastrointestinal Neoplasms 1 Gastrointestinal Diseases 1 Endocrine System Diseases 1 Endocrine Gland Neoplasms 1 Digestive System Diseases 1 Breast Neoplasms 1 Advanced Gastroenteropancreatic Neuroendocrine Tumor 1

Interventions

Radiosurgery 3 Androgen Antagonists 3 pembrolizumab 1 fludrocortisone acetate 1 enzalutamide 1 darolutamide 1 cabazitaxel 1 Radiotherapy, Image-Guided 1 Radiotherapy 1 Prednisone 1 Pluvicto 1 Lutetium-177 1 Lutetium 1 Hydrocortisone 1 Gonadotropin-Releasing Hormone 1 Docetaxel 1 Dexamethasone 1 Carboplatin 1 Abiraterone Acetate 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Prostate Cancer Metastatic × Lutetium-177 × Clear all

NCT06320067 2025-09-26

STAMPEDE2

University College, London

Phase 3 Recruiting

Prostate Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡